uniQure N.V. filed a Form 8-K on November 2, 2026, disclosing that the U.S. Food and Drug Administration has accepted for review the company's Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease submitted under the Accelerated Approval pathway.

Key Highlights

  • BLA Accepted: The FDA has accepted for review the Biologics License Application for ifezuntirgene inilparvovec for the treatment of Huntington's disease under the Accelerated Approval pathway.
  • Priority Review Granted: The application has been granted Priority Review with a PDUFA target action date of May 1, 2027.
  • Advisory Committee Planned: According to the filing, the FDA stated in its acceptance letter that it is tentatively planning to discuss the application at an Advisory Committee meeting.
  • Confirmatory Study Design: The company and FDA have aligned on a randomized, standard-of-care confirmatory trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity as the primary endpoint at 36 months.
  • Screening Timeline: The company disclosed plans to initiate patient screening in the U.S. by the end of 2026.
  • FDA Designations: Ifezuntirgene inilparvovec holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations from the FDA, according to the filing.

uniQure Discloses FDA BLA Acceptance and PDUFA Date for Huntington's Therapy

According to the Form 8-K filed by uniQure N.V. (NASDAQ:QURE) on November 2, 2026, the FDA has accepted for review the company's Biologics License Application for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease. The application was submitted under the Accelerated Approval pathway and has been granted Priority Review. The PDUFA target action date is May 1, 2027. The filing further noted that the FDA stated in its acceptance letter that it is tentatively planning to hold an Advisory Committee meeting to discuss the application.

The filing states that the BLA is supported by a previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database, as announced on September 24, 2025. The company disclosed that it and the FDA have aligned on key elements of the confirmatory study design, which is structured as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity as the primary endpoint at 36 months.

The filing describes ifezuntirgene inilparvovec as "the first investigational therapy for Huntington's disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA," and notes it also holds Fast Track designation. The company disclosed plans to initiate patient screening in the U.S. by the end of 2026. The filing contains forward-looking statements, which the company identified as subject to risks and uncertainties described in its periodic regulatory filings, including the risk that FDA may conclude trial data are insufficient to support accelerated approval.

What Was Disclosed

uniQure N.V. disclosed via an 8-K dated November 2, 2026 that the FDA accepted its BLA for ifezuntirgene inilparvovec under the Accelerated Approval pathway, granted Priority Review, set a PDUFA target action date of May 1, 2027, and is tentatively planning an Advisory Committee meeting.